Rafael Holdings, Inc. (RFL)

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C (NPC), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate. The company is also involved in developing Promitil, a pegylated liposomal mitomycin-C lipidic prodrug which is designed molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form. In addition, it develops surgical and procedural devices, including orthopedic arthroscopy instrument for carpal and cubital tunnel syndrome. Further, the company provides technological solutions specifically engineered for increased bioavailability of cannabinoids. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.